Swiss automation company ABB will invest $150 million to build an advanced robotics factory in Shanghai, China where robots will be used for manufacturing robots. The advanced robotics factory known as Kangqiao manufacturing center will come up near ABB’s China robotics campus. Expected to commence operations by the end of 2020, advanced robotics factory will […]
Novartis acquisition of Endocyte : US biopharma company Endocyte has agreed to be acquired by Swiss pharma company Novartis in a deal worth around $2.1 billion. As per the latest pharma acquisition news, Novartis has gone ahead with the deal to enlarge its expertise in radiopharmaceuticals for treating various types of cancers. Novartis Acquisition of […]
Swiss pharmaceutical company Novartis has announced a strategic acquisition of the US-based biopharma firm Endocyte for approximately $2.1 billion. This move aims to bolster Novartis’s capabilities in radiopharmaceuticals, particularly for cancer treatment. The acquisition will see Novartis purchase all outstanding shares of Endocyte at $24 per share. Expanding Expertise in Radiopharmaceuticals Endocyte specializes in developing […]
Roivant Sciences has launched a new biopharma company, Respivant Sciences, to focus on cutting-edge treatments for severe respiratory conditions. The newly established Respivant Sciences will be led by Bill Gerhart as CEO, Ahmet Tutuncu as Executive Vice President for Clinical and Regulatory, and Pravin Soni as Executive Vice President for Development and Manufacturing. This new […]
Energy acquisition news : Transocean, a Swiss offshore drilling contractor, has agreed to acquire its peer Ocean Rig, a Greece-based operator of semi-submersible oil rigs and UDW drillships, for $2.7 billion in a cash-cum-stock deal. Transocean acquisition of Ocean Rig is expected to help the Swiss firm bolster its fleet of ultra-deepwater and harsh-environment floating […]
Urovant Sciences has secured global licensing rights from Ion Channel Innovations for the development and commercialization of a promising gene therapy, hMaxi-K. This therapy is currently under development as a potential treatment for patients with overactive bladder (OAB) who have not found relief through traditional oral pharmacologic therapies. This comes at a time when there […]
Swiss pharmaceutical giant Novartis has announced encouraging results from the TRANSITION phase 4 clinical trial, affirming that Entresto (sacubitril/valsartan) can be safely initiated early in a broad range of patients with heart failure with reduced ejection fraction (HFrEF), shortly after stabilization from an acute heart failure episode. This groundbreaking study underlines the effectiveness of Entresto […]
In a strategic move to bolster its dermatology portfolio, Swiss pharmaceutical giant Novartis has entered into an agreement with MorphoSys and Galapagos to acquire exclusive global development and marketing rights for the atopic dermatitis drug, MOR106. This deal, potentially worth up to $1.1 billion, underscores Novartis’ commitment to advancing care in immuno-dermatology. Under the terms […]
Novartis, a Swiss pharmaceutical giant, has confirmed a substantial acquisition of AveXis, a US-based gene therapy company, for a total of $8.7 billion. This strategic move is set to enhance Novartis’s capabilities in gene therapy and neuroscience, particularly in the treatment of spinal muscular atrophy (SMA). Strategic Acquisition in Pharma Under the agreement, Novartis will […]
In a major strategic shift, GlaxoSmithKline (GSK) has finalized an agreement to acquire Novartis’ 36.5% stake in their consumer healthcare joint venture for $13 billion. This move comes shortly after GSK withdrew from a $20 billion bid to purchase Pfizer’s consumer healthcare business, indicating a focused realignment of GSK’s investment towards owning 100% of its […]